Prior authorization: document endemic travel and covered clinical indication

Coverage requires documentation that testing is being ordered for an individual with history of travel to a region endemic for Lyme and for a specific clinical indication consistent with the policy's covered presentations (e.g., early or later signs/symptoms, acute myocarditis/pericarditis, meningitis/encephalitis/myelitis, radiculoneuritis, mononeuropathy multiplex, acute cranial neuropathy).

• Documentation must show travel to a Lyme-endemic region when applicable.
• Record the specific clinical indication from the policy's covered list.

Prior authorization for listed procedure codes: no explicit PA stated

The policy does not state explicit prior authorization requirements for the listed CPT/HCPCS and proprietary codes; providers should follow standard payer submission rules and include the clinical documentation that supports medical necessity when submitting claims.

• No CPT-specific prior authorization statement appears in the policy excerpt.
• Attach clinical notes showing the covered indication when submitting testing codes.

Applicable procedure codes: list and operational guidance

The following CPT/HCPCS and proprietary codes are listed as applicable procedure codes for Lyme disease testing; ensure coding on claims matches documentation and any off-cycle additions noted in the revision history.

• Include codes such as 86617, 86618, 87475, 87476, 0041U, 0042U, 0316U and off-cycle additions 0580U and 0615U as appropriate on claims.
• Match the selected procedure code to the specific test performed and the supporting clinical documentation.

Preferred diagnostic algorithm: two-tier serologic testing

Use a two-tier serologic testing approach: perform a sensitive EIA or IFA as the first step, and if positive or equivocal, proceed to a confirmatory western immunoblot or an FDA-cleared second EIA (modified two-tier testing).

• If first-step EIA/IFA is negative, no further testing of that specimen is recommended.
• When FDA-cleared second-tier EIA is used, it replaces the western immunoblot as the confirmatory test per CDC guidance.

Recommended testing sequence: EIA/IFA then reflex confirmatory testing

Follow a two-step testing sequence: first-tier EIA or IFA; if the result is positive or equivocal, reflex to an immunoblot (western blot) or an FDA-cleared second EIA per CDC/AAP/NICE recommendations.

• If the first-tier EIA/IFA is negative, no further testing of the specimen is indicated.
• Perform second-tier testing only when first-tier is positive or equivocal.

Required clinical documentation: travel/exposure and signs/symptoms

Document the individual's history of travel to a Lyme-endemic region when applicable, and record signs and symptoms consistent with early or later Lyme disease as defined in Note 1.

• Include travel/exposure history (e.g., outdoor activities, contact with wildlife) when relevant.
• Reference Note 1 for the list of early and later signs/symptoms to justify testing.

Required clinical documentation: signs/symptoms, exposure, and timing

Document specific clinical signs or syndromes (e.g., erythema migrans when applicable, neurologic syndromes, arthritis, myocarditis) and epidemiologic exposure, and record timing of specimen collection (acute vs convalescent) relative to symptom onset.

• Specify the clinical presentation from the policy's covered list (e.g., meningitis, radiculoneuritis, Lyme arthritis).
• Note timing of symptoms and specimen collection to support serologic interpretation.

Repeat serologic testing documentation: persistent symptoms and interval

When repeating serologic testing after a prior negative result, document persistent symptoms and ensure the repeat test is performed no sooner than four weeks after the previous serologic test.

• Record clinical persistence of symptoms as the reason for repeat testing.
• Verify that at least four weeks have passed since the prior serologic test before repeating.

Triggers for denial: asymptomatic screening, EM, or lack of clinical support

Claims for serologic testing may be denied when testing is ordered for asymptomatic individuals, for persons with erythema migrans (EM) where laboratory testing is not indicated, or when testing is performed without clinical or epidemiologic support as defined in the policy.

• Testing asymptomatic individuals or routine screening is not covered.
• EM lesions should be clinically diagnosed and treated without laboratory testing.

Improper testing scenarios that risk denial

Testing scenarios that risk denial include serologic testing of asymptomatic patients after a tick bite, ordering tests without clinical or epidemiologic support, and performing a western immunoblot without a prior EIA/IFA.

• Do not order serology for asymptomatic individuals following a tick bite.
• Avoid ordering western immunoblot as the initial test if no prior EIA/IFA was performed or if first-tier is negative.

Asymptomatic screening and nonspecific symptoms: not supported

Do not screen asymptomatic individuals (including those in endemic areas); testing for nonspecific or vague symptoms without meeting the policy's defined symptomatic criteria is not supported and may be denied.

• Removed allowance for testing asymptomatic individuals living in endemic areas—screening is not supported.
• Testing for nonspecific symptoms was removed and is not covered unless the presentation meets defined criteria.